<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817479</url>
  </required_header>
  <id_info>
    <org_study_id>11892A</org_study_id>
    <nct_id>NCT00817479</nct_id>
  </id_info>
  <brief_title>Tumor Gene Expression in Women With Ovarian Cancer</brief_title>
  <official_title>Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to compare changes in expression of glucocorticoid-induced genes that
      may be involved in cell survival signaling in the tumors of ovarian cancer patients before
      and after an intraoperative dose of 20mg dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will examine the upregulation of dexamethasone-inducible genes in the tumors of
      ovarian cancer patients undergoing surgical debulking. A core biopsy of tumor will be taken
      at the first opportune time during surgery. Dexamethasone 20 mg IV will then be administered,
      and a second biopsy taken 30 minutes later. Samples at two and four hours later will also be
      obtained if surgery is still in progress and biopsiable tumor remains. Tissue will be
      snap-frozen. Subsequently tumor will be microdissected out from stroma, and tumor RNA will be
      extracted for gene expression profiling. Sixteen patients with epithelial ovarian cancer
      receiving dexamethasone will be studied, and an additional eight patients with epithelial
      ovarian cancer will receive a small saline (placebo) injection and serve as controls.
      Enrollment is limited to those patients with a serum albumin of at least 3.0 g/dL to minimize
      any theoretical adverse effect of a single dose of dexamethasone on wound healing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in SGK1 mRNA Expression Level</measure>
    <time_frame>&gt;= 30 min</time_frame>
    <description>Increase in SGK1 mRNA expression level is calculated as fold change = post / pre</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in MKP1/DuSP1 mRNA Expression Level</measure>
    <time_frame>&gt;= 30 min</time_frame>
    <description>Increase in MKP1/DuSP1 mRNA expression level is calculated as fold change = post / pre</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg of dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo [Saline]</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 MG OF DEXAMETHASONE OR PLACEBO</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo saline</description>
    <arm_group_label>Placebo [Saline]</arm_group_label>
    <other_name>Saline Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has intraabdominal disease either proven or strongly suspected to be ovarian
             or primary peritoneal cancer, and will be undergoing surgical debulking.

          -  Subject is not allergic to dexamethasone, and there is no obvious medical
             contraindication to dexamethasone.

          -  Subjects with diabetes requiring drug therapy are excluded.

          -  Subject is not currently receiving glucocorticoid therapy

          -  Nasal steroids (e.g. Flonase) are permitted

          -  Subject understands that this protocol does not have therapeutic intent

          -  Preoperative serum albumin at least 3.0 mg/dL

          -  Negative serum or urine pregnancy test in women of childbearing potential

          -  Signed informed consent

        Exclusion Criteria:

          -  Males do not get ovarian cancer and therefore will not be included in this trial.

          -  Patients of all ethnic backgrounds are eligible and will be encouraged to enroll.
             However we do not expect differences based on ethnicity, and this small study will not
             therefore be powered to make conclusions about ethnic differences in induction of
             GR-regulated genes with dexamethasone.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gini Fleming, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., et al.: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17(9): 2971-94.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 1;15(9):3196-204. doi: 10.1158/1078-0432.CCR-08-2131. Epub 2009 Apr 21.</citation>
    <PMID>19383827</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <results_first_submitted>June 2, 2016</results_first_submitted>
  <results_first_submitted_qc>June 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2016</results_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subject has intraabdominal disease either proven or strongly</keyword>
  <keyword>suspected to be ovarian or primary peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled between July 2003 and September 2007 through the Gynecologic Oncology Clinic at the University of Chicago subject to the inclusion and exclusion criteria described in the registration record.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo [saline]</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone</title>
          <description>20 mg dexamethasone IV push</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo [saline]</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone</title>
          <description>20 mg dexamethasone IV push</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="46" upper_limit="80"/>
                    <measurement group_id="B2" value="53.5" lower_limit="44" upper_limit="73"/>
                    <measurement group_id="B3" value="56" lower_limit="44" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Increase in SGK1 mRNA Expression Level</title>
        <description>Increase in SGK1 mRNA expression level is calculated as fold change = post / pre</description>
        <time_frame>&gt;= 30 min</time_frame>
        <population>Eighteen of the 20 randomized patients received treatment. Eight of the treated patients were unevaluable because there was not enough tissue available during surgery for experimental studies; the remaining 10 patients had adequate tissue samples at baseline and at least at 30 minutes following dexamethasone/normal saline administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo [saline]</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>20 mg dexamethasone IV push</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in SGK1 mRNA Expression Level</title>
          <description>Increase in SGK1 mRNA expression level is calculated as fold change = post / pre</description>
          <population>Eighteen of the 20 randomized patients received treatment. Eight of the treated patients were unevaluable because there was not enough tissue available during surgery for experimental studies; the remaining 10 patients had adequate tissue samples at baseline and at least at 30 minutes following dexamethasone/normal saline administration.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.4"/>
                    <measurement group_id="O2" value="6.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Increase in MKP1/DuSP1 mRNA Expression Level</title>
        <description>Increase in MKP1/DuSP1 mRNA expression level is calculated as fold change = post / pre</description>
        <time_frame>&gt;= 30 min</time_frame>
        <population>Eighteen of the 20 randomized patients received treatment. Eight of the treated patients were unevaluable because there was not enough tissue available during surgery for experimental studies; the remaining 10 patients had adequate tissue samples at baseline and at least at 30 minutes following dexamethasone/normal saline administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo [saline]</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>20 mg dexamethasone IV push</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in MKP1/DuSP1 mRNA Expression Level</title>
          <description>Increase in MKP1/DuSP1 mRNA expression level is calculated as fold change = post / pre</description>
          <population>Eighteen of the 20 randomized patients received treatment. Eight of the treated patients were unevaluable because there was not enough tissue available during surgery for experimental studies; the remaining 10 patients had adequate tissue samples at baseline and at least at 30 minutes following dexamethasone/normal saline administration.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.4"/>
                    <measurement group_id="O2" value="8.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Intra-operative assessment. Patients were not followed after surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo [saline]</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone</title>
          <description>20 mg dexamethasone IV push</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gini Fleming, MD</name_or_title>
      <organization>The University of Chicago, Department of Medicine</organization>
      <phone>(773) 702-6149</phone>
      <email>gfleming@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

